A week is a long time in politics—and, for prostate cancer patients, a revealing one.

Op-Ed: Danny Bedingfield

In Cambridge, Simeon Brown stood before men living with prostate cancer and offered an apology, but little else. He acknowledged New Zealand lags behind in early detection and treatment. He conceded the need for better screening. But in the end, his message was simple: no promises, no timelines—just “we’re working on it.”

Days later, he announced something very different.

The Government had lowered the bowel screening age from 60 to 58, expanding access to tens of thousands more New Zealanders. It was decisive, specific, and backed by a clear plan—staged rollout, workforce considerations, and non-invasive tools to manage demand. Most importantly, it will save lives.

For prostate cancer patients, the contrast was stark.

Every year, around 4000 New Zealand men are diagnosed with prostate cancer and about 700 die from it. Behind those numbers are fathers, partners, brothers. And behind many of those deaths is a system that still relies too heavily on late detection.

Brown is right about the constraints. MRI capacity is stretched. Specialist workforce shortages are real. Waiting lists are too long. These are not minor operational issues; they are structural barriers to any meaningful national screening programme. Without imaging capacity and trained clinicians, even the best policy intentions stall.

But the bowel screening expansion shows those same constraints can be managed when there is political will. The rollout has been deliberately staged to ensure colonoscopy services can cope. The introduction of home testing for symptomatic patients is expected to reduce unnecessary procedures and prioritise those at highest risk. In short, the system is being reshaped to make screening possible—not used as a reason to defer it.

That same mindset now needs to be applied to prostate cancer.

The case for action has already been made—clearly, repeatedly, and with growing urgency by groups like the Prostate Cancer Foundation of New Zealand. What we’re asking for is not radical. It is measured, evidence-based, and comparatively inexpensive: a $6.4 million, four-year pilot of a PSA-based screening programme.

In government spending terms, that is a rounding error. In human terms, it is transformative.

Advances in diagnostics—particularly better imaging and more precise testing pathways—have addressed many of the historic concerns about overdiagnosis and overtreatment. International evidence now points in a different direction: structured early detection programmes can significantly reduce mortality. In some cases, by as much as half.

If that holds true here, the question is no longer whether New Zealand can afford to trial screening. It is whether we can afford not to.

Minister Brown pointed to the role of community groups, including the Cambridge Prostate Cancer Support Group, to which he spoke, in raising awareness and supporting patients. He is right. These organisations fill gaps the health system cannot. They reach men who might otherwise avoid check-ups. They provide support that extends beyond clinical care.

But they cannot build MRI suites. They cannot train urologists. They cannot approve or fund new medicines.

That responsibility sits squarely with government. Budget 2026 provides an opportunity!

The proposed pilot—focused on regions like Tairāwhiti and Waitematā—would do more than test screening logistics. It would generate local data on how best to reach at-risk men, how to integrate modern diagnostics, and how to build a workforce capable of scaling up. It is, in effect, a cautious first step toward a national programme.

And it comes with a compelling economic argument: an estimated return of over $100 million to the health system through earlier intervention and reduced treatment costs.

There is also a broader equity dimension. Māori and rural men often face worse outcomes, driven in part by later diagnosis and reduced access to care. A targeted pilot could begin to address these disparities, rather than entrench them.

The Government has already accepted the principle that earlier screening saves lives. It has acted on that principle for bowel cancer and deserves credit for doing so. And it has two screening programmes for women – looking for cervical and breast cancer.

But us blokes - the prostate cancer patients, the survivors like me, and those who have lost a loved one - are asking why not us, why not here, and why not now?

Budget 2026 is approaching. The proposal is on the table. The precedent has been set.

“We’re working on it” is no longer enough. Men and their families need action now!  

-ENDS-

Danny Bedingfield, diagnosed with aggressive prostate cancer in 2013, is President of Prostate Cancer Foundation of New Zealand - Te Kāhui Mate Pukupuku Repe Tātea o Aotearoa Manatōpū